BillionToOne, Inc. (BLLN)
NASDAQ: BLLN · Real-Time Price · USD
99.30
+5.98 (6.41%)
At close: Nov 18, 2025, 4:00 PM EST
99.99
+0.69 (0.69%)
After-hours: Nov 18, 2025, 4:17 PM EST

Company Description

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics.

The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection.

It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment.

The company was incorporated in 2016 and is headquartered in Menlo Park, California.

BillionToOne, Inc.
CountryUnited States
Founded2016
IPO DateNov 6, 2025
IndustryDiagnostics & Research
SectorHealthcare
Employees620
CEOOguzhan Atay

Contact Details

Address:
1035 O’Brien Drive
Menlo Park, California 94025
United States
Phone(650) 460-2551
Websitebilliontoone.com

Stock Details

Ticker SymbolBLLN
ExchangeNASDAQ
Stock TypeCommon Stock
Share ClassClass A Shares
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$60.00
CIK Code0002070849
ISIN NumberUS0901681058
Employer ID81-1082020
SIC Code8071

Key Executives

NamePosition
Oguzhan Atay, PhDChief Executive Officer and Chair of the Board
David Tsao, PhDPresident, Chief Technology Officer and Director
Ross TaylorChief Financial Officer
Shan Riku SakakibaraChief Product Officer
Thomas LynchGeneral Counsel, Chief Compliance Officer and Secretary
Nancy JohnsonSenior Vice President of Sales and Commercial Operations
John ten Bosch, PhDSenior Vice President of Laboratory Operations
John ListerChief Administrative Officer
Thomas BremnerDirector
Firat IleriDirector

Latest SEC Filings

DateTypeTitle
Nov 10, 20258-KCurrent Report
Nov 6, 2025424B4Prospectus
Nov 6, 2025S-8Securities to be offered to employees in employee benefit plans
Nov 5, 2025CERTCertification by an exchange approving securities for listing
Nov 3, 20258-A12BRegistration of securities
Oct 17, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Oct 7, 2025S-1General form for registration of securities under the Securities Act of 1933
Sep 17, 2025DRS/A[Amend] [Cover] Draft Registration Statement
Aug 11, 2025DRS/A[Amend] [Cover] Draft Registration Statement
Jun 20, 2025DRS[Cover] Draft Registration Statement